IONIS HBV LRx

Drug Profile

IONIS HBV LRx

Alternative Names: GSK 3389404; GSK-404; ISIS GSK6 LRx

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis
  • Developer GlaxoSmithKline
  • Class Antisense elements; Antisense oligonucleotides; Antivirals
  • Mechanism of Action Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 20 Oct 2017 Adverse events data from a phase I trial in Hepatitis B presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 01 Feb 2017 Phase-II clinical trials in Hepatitis B in Hong Kong (SC) (NCT03020745)
  • 16 Jan 2017 GlaxoSmithKline plans a phase II trial for Hepatitis B in Hong Kong (SC) (NCT03020745)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top